Complete Remission and Radical Resection of Metastatic Inflammatory Breast Cancer Using Bevacizumab, Paclitaxel, and Fulvestrant

In most cases, unresectable metastatic breast cancer (MBC) is incurable. We report a case of bilateral inflammatory breast cancer with multiple pulmonary and distant lymph node metastatic lesions, achieving complete remission of distant metastases and curative resection of the primary lesions through combined regimen of bevacizumab, paclitaxel, and fulvestrant. A 65-year-old female patient presented with hormone receptor-positive, HER2-negative breast cancer with extensive inflammatory changes in the bilateral breast and skin, accompanied by multiple pulmonary and distant lymph node metastatic lesions. Treatment with bevacizumab, paclitaxel, and fulvestrant, resulted in complete remission of distant metastases and primary lesion reduction, enabling curative resection. At 54 months from treatment initiation and 42 months post-surgery, the patient remained disease-free. Based on this case, the combined use of bevacizumab, paclitaxel, and fulvestrant might eradicate distant metastases and facilitate curative resection in unresectable primary tumors. This treatment should be considered in patients with inoperable MBC.